In the plasma of patients with NSCLC under treatment with nivolumab, the concentrations of Granzyme B resulted significantly higher in responders rather than non-responder ones, suggesting a stronger activation of the CD8 T cytotoxic immune response (66). Here, GZMB is linked to non-small cell lung carcinoma.